LGND Q2 2023 Earnings — Ligand Pharmaceuticals Incorporated Revenue & Financial Results | Market Cap Arena

LGNDLigand Pharmaceuticals Incorporated

$4B

Q2 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$26M-47.4% YoY

Gross Profit

$25M93.7% margin

Operating Income

-$2M-7.5% margin

Net Income

$2M8.7% margin

EPS (Diluted)

$0.13

QoQ Revenue Growth

-40.0%

Cash Flow

Operating Cash Flow

-$82,000

Free Cash Flow

-$285,000

Stock-Based Comp.

$7M

Balance Sheet

Total Assets

$758M

Total Liabilities

$93M

Stockholders' Equity

$665M

Cash & Equivalents

$28M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$26M	$50M	-47.4%
Gross Profit	$25M	$38M	-34.6%
Operating Income	-$2M	$9M	-122.9%
Net Income	$2M	-$895,000	+355.9%

Revenue Segments

Royalty

$20M39%

Kyprolis

$8M15%

Material Sales, Captisol, Core

$5M10%

Material Sales, Captisol

$5M10%

Teriparatide Injection

$4M7%

Royalty, Other

$3M6%

Rylaze

$3M6%

Evomela

$2M4%

Contract Revenue

$716,0001%

License Fees

$508,0001%

License Fees, Milestones, and Product, Other, Product, Other

$208,0000%